Late-breaking poster presentation to highlight new immunogenicity data from ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancerBOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the Company will present a late-breaking update on clinical immunogenicity results from its ongoin ...

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient populationPatients treated with ELI-002 7P represented a diverse HLA repertoire including 1,132 unique types identified among 1,398 total HLA backgrounds in assessed patients99% (88/89) of patients assessed for HLA background induced mKRAS-specific T cell responses after treatment with ELI-002 7PInduction of mKRAS-specific T cell responses suggest that ...